Editas Medicine, Inc.
Editas Medicine, Inc.（EDIT）内幕交易
基于 SEC Form 4 的买入/卖出笔数、买卖比与情绪标签；可在本季度与近12个月之间切换；下方为季度图与交易明细。
SEC EDGAR · FMP · EDIT · 截至 2026年6月8日
活动摘要
买入笔数
0
P-Purchase only
卖出笔数
14
近12个月
买卖比
0.00
Buy/Sell (by trades)
整体情绪
Editas Medicine, Inc.内部人在过去近12个月主要在卖出股份，卖出行为通常由预设的Rule 10b5-1计划驱动，不一定代表对公司的负面看法。
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 买入仅计P-Purchase · 卖出仅计S-Sale
截至 2026年6月8日
EDIT 季度内部人买卖趋势
EDIT 内幕交易卖出 · EDIT 内幕交易买入 · 季度活动
Mobile shows last 4Q · Desktop shows full 8Q
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 最近8季度
As of Jun 8, 2026
活跃内部人
近12个月交易最活跃 · EDIT CEO内幕交易
显示全部内部人 · 点击卡片过滤下方交易表
▸ 按reportingName聚合 · 近12月交易次数Top5 · 无额外API
近期内幕交易记录
EDIT 高管卖出股份 · EDIT 董事内幕交易 · SEC Form 4申报
横向滑动查看全部列
| 日期 | 内部人 | 类型 | 股数 | 总金额 | 申报 |
|---|---|---|---|---|---|
| Jun 3, 2026 | Parison Amy SVP, Chief Financial Officer | Sale | 464 | $1K | Form 4 |
| Jun 3, 2026 | O'Neill Gilmore Neil CEO · Director | Sale | 15,380 | $42K | Form 4 |
| Jun 3, 2026 | Burkly Linda EVP, CHIEF SCIENTIFIC OFFICER | Sale | 731 | $2K | Form 4 |
| Mar 3, 2026 | O'Neill Gilmore Neil CEO · Director | Sale | 5,394 | $11K | Form 4 |
| Mar 3, 2026 | Parison Amy SVP, Chief Financial Officer | Sale | 474 | $957 | Form 4 |
| Mar 3, 2026 | Burkly Linda EVP, CHIEF SCIENTIFIC OFFICER | Sale | 749 | $2K | Form 4 |
| Dec 3, 2025 | Burkly Linda EVP, CHIEF SCIENTIFIC OFFICER | Sale | 713 | $2K | Form 4 |
| Dec 3, 2025 | O'Neill Gilmore Neil CEO · Director | Sale | 5,603 | $12K | Form 4 |
| Dec 3, 2025 | Parison Amy SVP, Chief Financial Officer | Sale | 461 | $993 | Form 4 |
| Sep 3, 2025 | Burkly Linda EVP, CHIEF SCIENTIFIC OFFICER | Sale | 710 | $2K | Form 4 |
| Sep 3, 2025 | Parison Amy SVP, Chief Financial Officer | Sale | 458 | $1K | Form 4 |
| Sep 3, 2025 | O'Neill Gilmore Neil CEO · Director | Sale | 5,592 | $15K | Form 4 |
| Aug 7, 2025 | Parison Amy SVP, Chief Financial Officer | Sale | 679 | $2K | Form 4 |
| Jul 31, 2025 | Burkly Linda EVP, CHIEF SCIENTIFIC OFFICER | Sale | 5,121 | $13K | Form 4 |
| Jun 3, 2025 | Parison Amy SVP, Chief Financial Officer | Sale | 446 | $769 | Form 4 |
| Jun 3, 2025 | Burkly Linda EVP, CHIEF SCIENTIFIC OFFICER | Sale | 726 | $1K | Form 4 |
| Jun 3, 2025 | O'Neill Gilmore Neil CEO · Director | Sale | 15,192 | $26K | Form 4 |
| Mar 4, 2025 | Lucera Erick EVP, CHIEF FINANCIAL OFFICER | Sale | 4,109 | $7K | Form 4 |
| Mar 4, 2025 | O'Neill Gilmore Neil CEO · Director | Sale | 16,632 | $28K | Form 4 |
| Mar 4, 2025 | Burkly Linda EVP, CHIEF SCIENTIFIC OFFICER | Sale | 2,891 | $5K | Form 4 |
| Dec 3, 2024 | O'Neill Gilmore Neil CEO · Director | Sale | 1,618 | $3K | Form 4 |
| Dec 3, 2024 | Mei Baisong EVP, CHIEF MEDICAL OFFICER | Sale | 541 | $1K | Form 4 |
| Sep 4, 2024 | Mei Baisong EVP, CHIEF MEDICAL OFFICER | Sale | 518 | $2K | Form 4 |
| Sep 4, 2024 | O'Neill Gilmore Neil CEO · Director | Sale | 1,555 | $5K | Form 4 |
| Jul 25, 2024 | Burkly Linda EVP, CHIEF SCIENTIFIC OFFICER | Sale | 11,886 | $64K | Form 4 |
⚡ = 金额≥$100万 · Award/Option价格显示— · 仅Form4 · 仅普通股
▸ 数据来源：SEC EDGAR · Form 4 申报 · ⚡ = 金额≥$100万 · Award/Option 价格显示 —
关于 EDIT 内幕交易
EDIT 内幕交易
Editas Medicine, Inc.（EDIT）内幕交易数据来源于公司内部人（包括Parison Amy (SVP, Chief Financial Officer), Burkly Linda (EVP, CHIEF SCIENTIFIC OFFICER), O'Neill Gilmore Neil (CEO · Director)）提交的SEC Form 4申报文件。过去12个月内，3位内部人向SEC提交了交易申报。EDIT内部人近期主要在卖出，这可能反映预设的10b5-1计划执行，而非方向性判断。
如需查看Editas Medicine, Inc.机构持仓比例和内部人持股百分比，请访问持仓（Ownership）标签页 → Ownership tab →
常见问题
EDIT 内幕交易 · 5个问题Editas Medicine, Inc.（EDIT）的内部人包括高管和董事，如Parison Amy (SVP, Chief Financial Officer), Burkly Linda (EVP, CHIEF SCIENTIFIC OFFICER), O'Neill Gilmore Neil (CEO · Director)等。过去12个月内，3位内部人向SEC提交了Form 4交易申报。内部人须在交易日期后2个工作日内完成申报。
▸ 数据来源：FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · RSU归属不计入情绪 · As of Jun 8, 2026